Pharmaceutical application of hydrogen sulfide donor

Abstract

The invention provides pharmaceutical application of a hydrogen sulfide donor, particularly relates to application of hydrogen sulfide and a hydrogen sulfide donor in preparation of medicines for treating aortic aneurysm and aortic dissection, and particularly relates to application of sodium hydrosulfide, DATS, L-cysteine and analogues thereof, GYY4137, ADT-OH and analogues thereof, and Gem-dithiol and analogues thereof in preparation of medicines for treating aortic aneurysm and aortic dissection. According to the invention, through an integral animal model, the hydrogen sulfide and the hydrogen sulfide donor are determined to be capable of reducing the occurrence rate and death rate of aortic aneurysm and aortic dissection, increasing the content of hydrogen sulfide in circulating blood, inhibiting expression of inflammatory factors in the process of aortic aneurysm and aortic dissection, and improving loss of smooth muscle cells in the process of aortic aneurysm and aortic dissection. The hydrogen sulfide donor can be used as a treatment medicine for improving occurrence and development of aortic aneurysm and aortic dissection.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of hydrogen sulfide donors in the preparation of medicines for treating aortic aneurysm and aortic dissection. Background technique [0002] Aortic aneurysm (AoA) and aortic dissection (AoD) are multifactorially induced and potentially fatal vascular diseases with a genetic predisposition. Aortic aneurysm manifests as aneurysmal dilation of the aorta, which is defined as dilation of the artery greater than 1.5 times the normal arterial diameter. Aortic dissection is manifested by tearing of the intima of the aortic wall, and circulating blood enters the media of the aortic wall through the intima breach, resulting in a large-scale tear of the media and the formation of a dissection. The etiology of more than 80% of patients with AoA and AoD is hypertension. According to statistics, AoA and AoD account for 1%-3% of the adult male mortality of 65-85...

AI Technical Summary

Problems solved by technology

However, whether hydrogen sulfide changes during the occurrence of aortic aneurysm and aortic dissection and whether it is involved in inflammatory injury and smooth muscle loss in aortic aneurysm and aortic dissection has not been reported

In addition, whether hydrogen sulfide donor has a therapeutic effect on the occurrence and development of aortic aneurysm and aortic dissection, there is still no relevant research

Images